NEWS DESK

INM Stock News, News Score & What It Could Mean

InMed Pharmaceuticals Inc. - Common Shares (INM) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently mixed earnings tone.

HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
OPEN ON TRADINGVIEW ↗TRADE THIS STOCK
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$1.59
Trend Context
Mixed / range
Latest briefing

What's happening with INM

seekingalpha.com15 Jul 2026

Artisan Mid Cap Fund Q2 2026 Performance Review

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com6 Jul 2026

Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com12 Jun 2026

Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
newsfilecorp.com
4 Jun 2026
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Read ↗
prnewswire.com
28 May 2026
Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?
Read ↗
globenewswire.com
27 May 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT
Read ↗
seekingalpha.com
25 May 2026
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
Read ↗
globenewswire.com
20 May 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
Read ↗
globenewswire.com
19 May 2026
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
Read ↗
Earnings news

INM earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

1
globenewswire.com27 May 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

2
globenewswire.com20 May 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating InMed Pharmaceuticals, Inc. (NASDAQ: INM ) related to its merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately 1.51% of the combined company. Is it a fair deal?

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your INM research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.
Stock AnalysisOPEN ON TRADINGVIEW ↗TRADE THIS STOCK